173 related articles for article (PubMed ID: 23635096)
21. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
[TBL] [Abstract][Full Text] [Related]
23. Candesartan effect on inflammation in hypertension.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Hypertens Res; 2010 Mar; 33(3):209-13. PubMed ID: 20075928
[TBL] [Abstract][Full Text] [Related]
24. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
Abe M; Okada K; Maruyama T; Maruyama N; Soma M; Matsumoto K
Expert Opin Pharmacother; 2010 Jul; 11(10):1611-20. PubMed ID: 20540652
[TBL] [Abstract][Full Text] [Related]
25. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Chaturvedi N;
Lancet; 2008 Oct; 372(9647):1385-93. PubMed ID: 18823658
[TBL] [Abstract][Full Text] [Related]
26. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Kim JA; Lee Y; Shin EK
Diabetes Care; 2006 Feb; 29(2):195-201. PubMed ID: 16443859
[TBL] [Abstract][Full Text] [Related]
27. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients.
Igarashi M; Hirata A; Yamaguchi H; Jimbu Y; Tominaga M
J Atheroscler Thromb; 2008 Feb; 15(1):34-40. PubMed ID: 18270461
[TBL] [Abstract][Full Text] [Related]
28. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M; Pfützner A; Forst T; Kleine I; Fuchs W
Cardiovasc Diabetol; 2011 Jul; 10():65. PubMed ID: 21756323
[TBL] [Abstract][Full Text] [Related]
29. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Lee Y; Shin EK
Int J Cardiol; 2006 Mar; 108(1):96-100. PubMed ID: 16246439
[TBL] [Abstract][Full Text] [Related]
30. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
Aso Y; Yamamoto R; Suetsugu M; Matsumoto S; Wakabayashi S; Matsutomo R; Takebayashi K; Inukai T
Diabet Med; 2007 Sep; 24(9):962-8. PubMed ID: 17509067
[TBL] [Abstract][Full Text] [Related]
32. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
33. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
34. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
Metabolism; 2008 Oct; 57(10):1473-8. PubMed ID: 18803955
[TBL] [Abstract][Full Text] [Related]
35. Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Omasu F; Oda T; Yamada M; Yoshizawa N; Yamakami K; Sakurai Y; Miura S
Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1292-8. PubMed ID: 17670902
[TBL] [Abstract][Full Text] [Related]
36. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
Rizzoni D; Porteri E; De Ciuceis C; Sleiman I; Rodella L; Rezzani R; Paiardi S; Bianchi R; Ruggeri G; Boari GE; Muiesan ML; Salvetti M; Zani F; Miclini M; Rosei EA
Hypertension; 2005 Apr; 45(4):659-65. PubMed ID: 15723969
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
[TBL] [Abstract][Full Text] [Related]
38. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus.
Derosa G; Cicero AF; Ciccarelli L; Fogari R
Clin Ther; 2003 Jul; 25(7):2006-21. PubMed ID: 12946547
[TBL] [Abstract][Full Text] [Related]
40. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2010 Feb; 28(2):340-52. PubMed ID: 19864959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
